Skip to main content

Table 4 Comparisons of clinical parameters, plasma fatty acids and desaturase activities grouping by rs174537 GG genotype

From: Polymorphisms in FADS1 and FADS2 alter plasma fatty acids and desaturase levels in type 2 diabetic patients with coronary artery disease

Characteristics Healthy controls
GG (n = 65)
T2D patients
GG (n = 88)
CAD patients
GG (n = 58)
T2D&CAD patients
GG (n = 63)
Total cholesterol (mmol/l) 4.50 ± 0.72* 4.79 (4.00, 5.30)* 4.05 (3.29, 4.60) 4.52 (3.59, 5.50)
Triglyceride (mmol/l) 0.97 (0.79, 1.22)* 1.71 (1.21, 2.33)* 1.31 (1.01, 1.60) 1.36 (1.05, 1.94)
HDL-cholesterol (mmol/l) 1.37 (1.10, 1.55)* 1.07 (0.90, 1.21) 1.10 (0.94, 1.37)* 1.10 (0.93, 1.35)
LDL-cholesterol (mmol/l) 2.74 (2.27, 3.29)* 2.81(2.10, 3.17)* 2.42 (1.83, 2.84) 2.75 (2.03, 3.53)
Fasting plasma glucose (mmol/l) 4.89 (4.58, 5.54)* 8.51 (6.56, 12.24)* 5.47 (5.01, 6.29)* 7.00 (6.08, 8.24)
Total saturated fatty acid 32.14 (31.21, 33.53) 32.88 (31.24, 34.39) 33.07 (31.21, 34.97) 32.86 (29.45, 34.20)
Palmitic acid, C16:0 22.17 (21.44, 23.58)* 23.62 (21.80, 25.37) 22.46 (21.27, 24.41) 23.96 (21.00, 25.09)
Stearic acid, C18:0 9.19 (8.51, 9.87)* 9.02 (7.62, 10.55) 9.24 (8.56, 10.19) 8.45 (6.86, 9.75)
Total monounsaturated fatty acid 16.13 (14.40, 18.27)* 18.93 (16.80, 21.12) 16.58 (15.04, 19.52) 18.21 (15.41, 20.39)
Palmitoleic acid, C16:1 0.73 (0.57, 0.96)* 0.65 (0.33, 1.30) 0.88 (0.55, 1.26) 1.00 (0.55, 1.67)
Oleic acid, C18:1n-9 15.09 (13.33, 16.89)* 18.00 (16.16, 20.07)* 15.38 (13.91, 17.65)* 16.83 (13.76, 18.70)
Total polyunsaturated n-3 fatty acid 3.92 (3.24, 4.56)* 6.74 (1.99, 10.07)* 3.40 (2.81, 4.09)* 5.37 (3.45, 8.51)
Alpha-linolenic acid, C18:3n-3 0.66 (0.47, 0.86)* 0.56 (0.12, 1.13) 0.59 (0.36, 0.79) 0.67 (0.33, 0.95)
Eicosapentaenoic acid, C20:5n-3 0.31 (0.10, 0.56) 0.75 (0.21, 1.52)* 0.28 (0.00, 0.47) 0.27 (0.00, 1.80)
Docosahexaenoic acid, C22:6n-3 2.94 (2.33, 3.36)* 4.32 (1.16, 6.91) 2.50 (1.98, 3.12)* 3.66 (2.72, 5.92)
Total polyunsaturated n-6 fatty acid 45.70 (43.71, 48.00)* 46.51 (43.40, 50.40) 43.94 (41.11, 48.44) 45.85 (41.87, 48.23)
Linoleic acid, C18:2n-6 36.21 (33.33, 39.64)* 35.13 (30.12, 45.38)* 32.59 (29.13, 35.74) 32.52 (27.44, 36.37)
Gamma-linolenic acid, C18:3n-6 0.24 (0.09, 0.32) 0.12 (0.01, 0.34) 0.38 (0.11, 0.58) 0.12 (0.00, 0.54)
Dihomo-gamma-linolenic acid, C20:3n-6 1.39 (1.11, 1.77)* 1.29 (0.10, 2.12) 1.67 (1.19, 2.13) 1.64 (0.93, 2.58)
Arachidonic acid, C20:4n-6 7.66 (6.24, 9.19)* 8.04 (3.97, 11.93) 8.13 (6.33, 10.43) 9.21 (6.50, 11.48)
Desaturase activity
C20:4n-6/C20:3n-6 (D5D) 5.54 (4.39, 7.30) 5.92 (4.33, 8.41)* 5.09 (3.47, 7.78) 4.20 (2.66, 6.85)
C20:4n-6/C18:2n-6 (D6D) 0.22 (0.16, 0.26)* 0.23 (0.09, 0.39)* 0.24 (0.19, 0.34) 0.29 (0.19, 0.38)
C16:1/C16:0 (D9D-16) 0.03 (0.02, 0.05) 0.03 (0.01, 0.06) 0.04 (0.03, 0.06) 0.04 (0.03, 0.07)
C18:1n-9/C18:0(D9D-18)1 1.64 (1.39, 2.00)* 1.86 (1.56, 2.43) 1.73 (1.44, 2.06)* 1.95 (1.69, 2.32)
n-3/n-6 0.08 (0.07, 0.10)* 0.15 (0.04, 0.23)* 0.08 (0.06, 0.09)* 0.11 (0.07, 0.21)
  1. * p < 0.0125 derived from two-independent nonparametric analysis with Bonferroni correction (T2D&CAD patients vs healthy controls or T2D patients or CAD patients)